Interestingly, CD133-Pyro augmented the targeting capacity of Pyro, and it was found that CD133-Pyro exhibits the targeted delivery ability both in CRCSCs and inhibited tumor growth in a mouse model, suggesting its applicability for the therapy of CRC via CRCSC targeting [134]. Here, PROM1 is linked to neoplasm.